Active Primary Sjögren’s Disease research hub

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease

This study tests a new injection called telitacicept for adults with active primary Sjögren's disease. Researchers want to see if this medicine works better and is safer than a dummy treatment (placebo) at lowering general disease activity, easing dryness, and improving daily symptoms over 48 weeks.